email   Email Us: info@lupinepublishers.com phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2638-5945

Open Access Journal of Oncology and Medicine

Review Article(ISSN: 2638-5945)

Peroxisome Proliferator-Activated Receptor Gamma (Pparγ) and Prostate Cancer Volume 5 - Issue 1

Xi Jin1#, Bandar A. Alenezi2#, Gang He3, Hongwen Ma1, Qiang Wei1, and Youqiang Ke1, 2, 3*

  • 1Department of Urology, Institute of Urology, West China Hospital, Sichuan University, China
  • 2Department of Molecular & Clinical Cancer Medicine, Liverpool University, Liverpool, United Kingdom
  • 3Sichuan Antibiotics Industrial Institute, Chengdu University, China
  • 4These authors contributed equally to this work

Received: November 25, 2021   Published: December 6, 2021

Corresponding author: Professor Youqiang Ke, Department of Molecular & Clinical Cancer Medicine, Liverpool University, United Kingdom.

DOI: 10.32474/OAJOM.2021.05.000206

 

Fulltext PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) is a transcription factor that is ligand dependent and is a member of the nuclear hormone receptor superfamily. PPARγ is expressed in two isoforms: PPARγ1 and PPARγ2, the latter contains thirty extra amino acids (Figure 1). Both synthetic and endogenous ligands can band to and activate PPARγ [1]. When activated, PPARγ is translocated into the nucleus and forms a heterodimer with the retinoid X receptor (RXR), where it serves as a transcriptional regulator of genes via DNA binding [2]. It is well established that PPARγ plays a critical role in adipocyte differentiation, the inflammatory response, and peripheral glucose consumption. PPARγ agonists are frequently utilised to treat type II diabetes [1]. Diabetes type II is the most prevalent endocrine-metabolic condition worldwide, characterised by insulin resistance and insulin secretion abnormalities. PPARγ agonists were utilised to sensitise tissues (muscle, adipose tissue, and liver) to insulin stimulation. However, these PPARγ agonist medicines were associated with significant side effects such as increased weight, oedema, heart failure, and an increased risk of myocardial infarction [3]. The role of PPARү in prostate cancer (PCa) has been controversial. Initially, it was believed that PPARγ functioned as a tumour suppressor in prostate cells since agonist ligands suppressed the proliferation of PCa cells.

Abstract| Peroxisome Proliferator-Activated Receptor Gamma| The Role of PPARγ in PCa| Role of PPARγ isoforms in prostate cancer| Acknowledgements| Competing Interest| References|

https://www.high-endrolex.com/21